Clinical trials: Macrovascular Invasion
Hepatocellular Carcinoma (HCC), Macrovascular Invasion
Using Radiotherapy and Immunotherapy to Treat Advanced Liver Cancer Before Transplant
The goal of this clinical trial is to learn if locoregional therapy and immunotherapy can be used together to help patients with hepatocellular carcinoma (HCC) and macrovascular invasion achieve liver transplantation.
- Conditions
- Hepatocellular Carcinoma (HCC), Macrovascular Invasion, Liver Transplant Surgery, Downstaging
- Trial name
- MacroTrans (NCT06725121)
- Testing
- Atezolizumab & Bevacizumab, Yttrium-90 (Y-90), Stereotactic body radiotherapy (SBRT)
- Where
- 2 sites in Canada
- Volunteers
- 48 people
- Sponsor
- University Health Network, Toronto
Resectable Hepatocellular Carcinoma, Macrovascular Invasion
Neoadjuvant SBRT Combined With Lenvatinib and Pucotenlimab for Resectable Hepatocellular Carcinoma
At the time of diagnosis, the majority of hepatocellular carcinoma (HCC) patients are at the intermediate to advanced stages, with a 50-70% incidence of macrovascular invasion (including portal vein, hepatic vein, inferior vena…
- Conditions
- Resectable Hepatocellular Carcinoma, Macrovascular Invasion, CNLC IIIA Stage
- Trial name
- NCT06524466
- Testing
- Neoadjuvant SBRT combined with Lenvatinib and Pucotenlimab
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Sun Yat-sen University